you're reading...
BLOG, Events

A novel approach for better delivery of precision medicines in Europe

Written by Gianluca Quaglio,

Research gap between drug development and real world healthcare delivery
Research gap between drug development and real world healthcare delivery © Pot Regnier/STOA

Introduction

The STOA workshop entitled ‘Innovative solution for research in healthcare’, chaired by Paul Rübig (EPP, AT), first STOA Vice-Chair, is an opportunity to discuss the implementation of an ‘innovation-centred’ system, exploring a truly ‘patient-centred’ paradigm with systematically coordinated applied clinical research carried out in conjunction with drug development. The workshop will be held on 10 January 2019, 9:30-12:30, at the European Parliament in Brussels (Altiero Spinelli building, room 5E2).


Webstream

#HealthSTOA


In 2015, the Council of the EU, while accepting that there is no common definition of the term precision (personalised) medicine, noted at the same time that this is generally understood to refer to a medical model, which uses the characterisation of individuals’ phenotypes and genotypes for tailoring the right therapeutic strategy for the right person at the right time, and/or for determining the predisposition to disease, and/or for delivering a targeted prevention strategy.

As the number of authorised drugs that target specific proteins implicated in the disease phenotype increases on the market, and as next-generation sequencing and other technologies bring comprehensive genome-wide analyses to affordable levels, precision medicine begins to play a much wider role in routine practice.

However, once a drug enters the market following regulatory approval, each EU Member State determines its real-world use based on its own criteria: pricing, reimbursement and clinical indications. Such an innovation-centred clinical research landscape might neglect patient-relevant issues in a real-world setting. There is a demand for reform of the current system to create a truly ‘patient-centred’ paradigm, with systematically coordinated treatment optimisation in conjunction with the drug development process.

Two disconnected stages: from drug development to real-world application

In Europe, most of the clinical research dedicated to therapeutic innovations in drugs aims primarily at regulatory approval. In this first stage, scientific issues on the efficacy of a new drug are addressed in selected patient populations and lead up to European Medicine Agency (EMA) approval.

Once a drug enters the market, the second stage begins, where research addresses clinically relevant questions to tailor the therapeutic indications to ‘real-life’ clinical practice. Due to this discontinuity between the first and the second stage, research during the second stage results – for various reasons – in suboptimal uptake of findings into practice or clinical guidelines.

Administration of improper treatment may generate unnecessary toxicity for patients, but also affects national healthcare budgets and adds cost to already highly priced treatments. Therefore, following the drug development phase, independent investigations are needed on the optimal use of medicines (known as ‘treatment optimisation’).

Regulatory approval

The regulatory approval of new treatments does not address clinical issues relevant to patients in real-world settings, such as: (i) how to combine new treatments with the existing therapeutic options; most patients may need some form of combination therapy, which is determined individually, based on a number of clinical and biomarker predictors; (ii) how to evaluate the clinical outcomes when new treatments are administered in off-label indications; (iii) how to determine the optimal scheme/treatment duration and at which benefit/risk ratio; (iv) what the long-term issues related to the treatment are. When addressed, the above-mentioned issues are studied mostly following EMA’s approval and rely on the goodwill and agendas of independent research groups.

Reasons for a lack of real-world evidence

There are a number of reasons for such lack of real-world evidence, mentioned briefly here. First, regulatory approval of new treatments requires data on ‘quality, safety and efficacy’ and not on ‘comparability’. This approach is centred on the innovative treatment, as its value is assessed in absolute terms, not relatively to the pre-existing therapeutic armamentarium of medicines, equipment and techniques available. Second, in order to maximise the experimental treatment effect, patients included in clinical trials represent only 2-4% of the overall targeted population, leading to a poor external validity of clinical trials. Finally, there is a lack of evidence that would make it possible to rank the multiple therapeutic options available and define the conditions for optimal care.

Aim of the STOA workshop

This workshop will provide patients, clinicians, payers, Health Technology Assessment (HTA) agencies, regulators, pharmaceutical companies, researchers, policy-makers and the public at large with an opportunity to present their point of view and their innovative suggestions for future drug development in Europe.

The establishment of a new developmental framework through close collaboration between industry, patient representatives, and regulatory, governmental, academic and other stakeholders would hopefully facilitate comparisons of assay performance before regulatory approval, harmonising the approval process. Such a framework could mitigate the somewhat problematic current situation. The issue is ubiquitous in modern biomarker/drug development processes and is not related to particular targets or pathways.

About Scientific Foresight (STOA)

The Scientific Foresight Unit (STOA) carries out interdisciplinary research and provides strategic advice in the field of science and technology options assessment and scientific foresight. It undertakes in-depth studies and organises workshops on developments in these fields, and it hosts the European Science-Media Hub (ESMH), a platform to promote networking, training and knowledge sharing between the EP, the scientific community and the media. All this work is carried out under the guidance of the Panel for the Future of Science and Technology (STOA), composed of 25 MEPs nominated by nine EP Committees. The STOA Panel forms an integral part of the structure of the EP.

Discussion

2 thoughts on “A novel approach for better delivery of precision medicines in Europe

  1. Please share the link to the manifesto for ‘developing a novel approach to deliver better precision medicine to patients’ on this page. Many thanks

    Like

    Posted by Lina Christensen | January 10, 2019, 12:13

Trackbacks/Pingbacks

  1. Pingback: A novel approach for better delivery of precision medicines in Europe | Vatcompany.net - January 8, 2019

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Download the EPRS App

EPRS App on Google Play
EPRS App on App Store
What Europe Does For You
EU Legislation in Progress
Topical Digests
EPRS Podcasts

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 3,045 other followers

RSS Link to Scientific Foresight (STOA)

Disclaimer and Copyright statement

The content of all documents (and articles) contained in this blog is the sole responsibility of the author and any opinions expressed therein do not necessarily represent the official position of the European Parliament. It is addressed to the Members and staff of the EP for their parliamentary work. Reproduction and translation for non-commercial purposes are authorised, provided the source is acknowledged and the European Parliament is given prior notice and sent a copy.

For a comprehensive description of our cookie and data protection policies, please visit Terms and Conditions page.

Copyright © European Union, 2014-2019. All rights reserved.

%d bloggers like this: